News

Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®

November 9, 2020

Florham Park, NJ, November 9th, 2020 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the FDA approval of Gemmily™ (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules), 1 mg/20 mcg, a therapeutically equivalent generic version of Taytulla®.  Xiromed is the first generic to Taytulla® approved in the United States.  […]


Xiromed LLC Announces the First Generic Launch of Fosfomycin Tromethamine Granules for Oral Solution, Generic to Monurol®

October 6, 2020

Xiromed LLC today announced the approval and launch of Fosfomycin Tromethamine Granules for Oral Solution, the first AA-rated generic version of Monurol® approved by the U.S. Food and Drug Administration.     Florham Park, NJ – Monurol® (fosfomycin tromethamine) granules for oral solution is a prescription antibiotic approved to treat uncomplicated urinary tract infections (UTI) […]


Xiromed LLC Announces the Launch of Three Generic Injectable Products

August 17, 2020

Xiromed LLC today announced that it has launched the first three injectable products from its strategic collaboration with Gland Pharma Ltd of Hyderabad, India: Irinotecan Injection USP, 20mg/mL, Glycopyrrolate Injection USP, 0.2mg/mL, and Neostigmine Methylsulfate Injection USP, available in two strengths: 5 mg/10 mL (0.5mg/mL) and 10 mg/10 mL (1mg/mL). These are the first injectable […]


Xiromed LLC Announces the Launch of Testosterone Gel 1.62% Metered Dose Pump (20.25mg/1.25g pump actuation), AB-Rated Generic to AndroGel® 1.62%

August 14, 2020

Xiromed LLC today announced the launch of Testosterone Gel 1.62% Metered Dose Pump (20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel® 1.62%.   AndroGel® 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.  Annual market sales for AndroGel® 1.62% and its generic equivalents for […]


Xiromed, LLC Enters into Strategic Collaboration with Gland Pharma Ltd

June 9, 2020

Xiromed, LLC, the New Jersey-based generic division of Insud Pharmaceuticals, announced today that it has entered into a long-term strategic collaboration with Gland Pharma Ltd, headquartered in Hyderabad, India.  The development and commercialization partnership covers a basket of generic injectable products developed by Gland, which will be marketed in the United States by Xiromed. The […]


Xiromed LLC Launches 6 New Generic Pharmaceutical Products

February 28, 2020

Xiromed LLC, a New Jersey-based generic pharmaceutical company, has launched 6 new generic pharmaceutical product in the US: Jaimiess™ (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP), generic to Seasonique®; LoJaimiess® (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP), generic to LoSeasonique®; Volnea® (Desogestrel and Ethinyl Estradiol Tablets, USP […]


Xiromed LLC Launches Commercial Operations

January 8, 2020

Xiromed LLC, a New Jersey-based generic pharmaceutical company, has launched commercial operations in the United States. With a comprehensive portfolio of generic pharmaceutical products, Xiromed is committed to providing high quality generics to patients in the US market. Beyond the current portfolio of commercial products already launched, Xiromed has a robust development portfolio of generic […]